HIV Drugs Market By Medication Class (Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Entry Inhibitors, HIV Integrase Strand Transfer

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,930	35 Pages	Allied Market Research	November, 2023	ALMR18447344

Best Price Guarantee
Price	from $3,930
Length	35 Pages
Publisher	Allied Market Research
Published Date	November, 2023
SKU	ALMR18447344

HIV Drugs Market By Medication Class (Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Entry Inhibitors, HIV Integrase Strand Transfer Inhibitors, Others), By Distribution Channel (Hospital Pharmacies, Drugs stores and retail pharmacies, Online pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

The HIV drugs market was valued at $32.8 billion in 2022 and is estimated to reach $51.1 billion by 2032, exhibiting a CAGR of 4.5% from 2023 to 2032. Human immunodeficiency virus (HIV) attacks the body’s immune system, leading to complete damage of the system and making the host system susceptible to infection. The virus attacks the CD4 cells, whose primary role is to help the immune system defend against infections, thus destroying the first line of defense of the human body and exposing the person to various infections. HIV is one of the most alarming and widespread diseases globally. The major route of transmission of HIV infection is through unprotected sex, use of contaminated needles, breast milk of HIV-infected mother to child, and infected blood.

Major factors that drive the growth of the global HIV drugs market include rapid advancements in treatment of HIV; rise in number of research regarding HIV drugs; and increase in number of patients suffering from HIV. For instance, according to the Joint United Nations Program on HIV and AIDS (UNAIDS), in 2022, the estimated total number of HIV patients is 2.2 million in Latin America. Furthermore, surge in demand for HIV drugs, increase in number of awareness programs regarding HIV, and rise in number of clinical trials for the development of HIV drugs boost the growth of HIV drugs market.

In addition, increase in target population, rise in diagnosis rate of HIV, and surge in the prevalence of HIV diseases propel the market growth. However, stringent government regulations for the approval and commercialization of HIV drugs are expected to restrict the growth of HIV drugs market. On the contrary, surge in healthcare expenditure and unmet medical demands to get better treatment options in developing countries are expected to create lucrative opportunities for the expansion of the global market in the future.

The HIV drugs market is segmented on the basis of medication class, distribution channel, and region. On the basis of medication class, the market is categorized into multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors, HIV integrase strand transfer inhibitors and others. The multi-class combination drugs segment is further categorized into Atripla, Complera, Prezcobix, Stribild, Genvoya, Odefsey, Symtuza, Triumeq, descovy, dovato and others. The nucleoside reverse transcriptase inhibitors (NRTIs) segment is further categorized into Emtriva, Epivir, Epzicom, Truvada, biktavry and others. The non-nucleoside reverse transcriptase inhibitors (NNRTIs) segment is further categorized into Edurant and others. The protease inhibitors (PIs) segment is further categorized into Aptivus, Kaletra, Lexiva/ Telzir, Norvir, Viracept and others. The entry inhibitors segment is further categorized into Selzentry, Fuzeon and Rukobia. The HIV integrase strand transfer inhibitors segment is further categorized into Isentress/Isentress HD, Tivicay, Apretude and Juluca.

On the basis of distribution channel, it is segregated into hospital pharmacies, drugs stores and retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

The major players profiled in the report are AbbVie Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GSK plc (ViiV Healthcare), Johnson & Johnson, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd. These major players have adopted product approval, partnership, and product launch as key developmental strategies to improve the product portfolio of the HIV drugs market.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hiv drugs market analysis from 2022 to 2032 to identify the prevailing hiv drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the hiv drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global hiv drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Medication Class

Multi-Class Combination Drugs
Brand
Atripla
Complera
Prezcobix
Stribild
Genvoya
Odefsey
Symtuza
Triumeq
Descovy
Dovato
Others
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Brand
Emtriva
Epivir
Epzicom/Kivexa
Truvada
Biktarvy
Others
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Brand
Edurant
Others
Protease Inhibitors (PIs)
Brand
Aptivus
Kaletra
Lexiva/ Telzir
Norvir
Viracept
Others
Entry Inhibitors
Brand
Selzentry
Fuzeon
Rukobia
HIV Integrase Strand Transfer Inhibitors
Brand
Isentress/Isentress HD
Tivicay
Apretude
Juluca
Others

By Distribution Channel

Hospital Pharmacies
Drugs stores and retail pharmacies
Online pharmacies

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Key Market Players

Merck & Co., Inc.
Cipla Ltd.
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
Gilead Sciences, Inc.
AbbVie Inc.
Boehringer Ingelheim International GmbH
Teva Pharmaceutical Industries Ltd.
GlaxoSmithKline plc
Johnson & Johnson

Please Note: It will take 7-10 business days to complete the report upon order confirmation.

CHAPTER 1: INTRODUCTION: 1.1. Report description; 1.2. Key market segments; 1.3. Key benefits to the stakeholders; 1.4. Research methodology; 1.4.1. Primary research; 1.4.2. Secondary research; 1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY: 2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW: 3.1. Market definition and scope; 3.2. Key findings; 3.2.1. Top impacting factors; 3.2.2. Top investment pockets; 3.3. Porter’s five forces analysis; 3.3.1. Low bargaining power of suppliers; 3.3.2. Low threat of new entrants; 3.3.3. Low threat of substitutes; 3.3.4. Low intensity of rivalry; 3.3.5. Low bargaining power of buyers; 3.4. Market dynamics; 3.4.1. Drivers; 3.4.1.1. Rise in cases of HIV; 3.4.1.2. Initiatives taken by various government associations to raise awareness about diagnosis and management of HIV/AIDS; 3.4.1.3. Introduction of generic drugs for HIV; 3.4.2. Restraints; 3.4.2.1. Stringent regulatory requirements for the approval and commercialization of HIV drugs; 3.4.3. Opportunities; 3.4.3.1. Increasing number of products in the pipeline
CHAPTER 4: HIV DRUGS MARKET, BY MEDICATION CLASS: 4.1. Overview; 4.1.1. Market size and forecast; 4.2. Multi-Class Combination Drugs; 4.2.1. Key market trends, growth factors and opportunities; 4.2.2. Market size and forecast, by region; 4.2.3. Market share analysis by country; 4.2.4. Multi-Class Combination Drugs HIV Drugs Market by Brand; 4.3. Nucleoside Reverse Transcriptase Inhibitors (NRTIs); 4.3.1. Key market trends, growth factors and opportunities; 4.3.2. Market size and forecast, by region; 4.3.3. Market share analysis by country; 4.3.4. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) HIV Drugs Market by Brand; 4.4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs); 4.4.1. Key market trends, growth factors and opportunities; 4.4.2. Market size and forecast, by region; 4.4.3. Market share analysis by country; 4.4.4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) HIV Drugs Market by Brand; 4.5. Protease Inhibitors (PIs); 4.5.1. Key market trends, growth factors and opportunities; 4.5.2. Market size and forecast, by region; 4.5.3. Market share analysis by country; 4.5.4. Protease Inhibitors (PIs) HIV Drugs Market by Brand; 4.6. Entry Inhibitors; 4.6.1. Key market trends, growth factors and opportunities; 4.6.2. Market size and forecast, by region; 4.6.3. Market share analysis by country; 4.6.4. Entry Inhibitors HIV Drugs Market by Brand; 4.7. HIV Integrase Strand Transfer Inhibitors; 4.7.1. Key market trends, growth factors and opportunities; 4.7.2. Market size and forecast, by region; 4.7.3. Market share analysis by country; 4.7.4. HIV Integrase Strand Transfer Inhibitors HIV Drugs Market by Brand; 4.8. Others; 4.8.1. Key market trends, growth factors and opportunities; 4.8.2. Market size and forecast, by region; 4.8.3. Market share analysis by country
CHAPTER 5: HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL: 5.1. Overview; 5.1.1. Market size and forecast; 5.2. Hospital Pharmacies; 5.2.1. Key market trends, growth factors and opportunities; 5.2.2. Market size and forecast, by region; 5.2.3. Market share analysis by country; 5.3. Drugs stores and retail pharmacies; 5.3.1. Key market trends, growth factors and opportunities; 5.3.2. Market size and forecast, by region; 5.3.3. Market share analysis by country; 5.4. Online pharmacies; 5.4.1. Key market trends, growth factors and opportunities; 5.4.2. Market size and forecast, by region; 5.4.3. Market share analysis by country
CHAPTER 6: HIV DRUGS MARKET, BY REGION: 6.1. Overview; 6.1.1. Market size and forecast By Region; 6.2. North America; 6.2.1. Key market trends, growth factors and opportunities; 6.2.2. Market size and forecast, by Medication Class; 6.2.3. Market size and forecast, by Distribution Channel; 6.2.4. Market size and forecast, by country; 6.2.4.1. U.S.; 6.2.4.1.1. Market size and forecast, by Medication Class; 6.2.4.1.2. Market size and forecast, by Distribution Channel; 6.2.4.2. Canada; 6.2.4.2.1. Market size and forecast, by Medication Class; 6.2.4.2.2. Market size and forecast, by Distribution Channel; 6.2.4.3. Mexico; 6.2.4.3.1. Market size and forecast, by Medication Class; 6.2.4.3.2. Market size and forecast, by Distribution Channel; 6.3. Europe; 6.3.1. Key market trends, growth factors and opportunities; 6.3.2. Market size and forecast, by Medication Class; 6.3.3. Market size and forecast, by Distribution Channel; 6.3.4. Market size and forecast, by country; 6.3.4.1. Germany; 6.3.4.1.1. Market size and forecast, by Medication Class; 6.3.4.1.2. Market size and forecast, by Distribution Channel; 6.3.4.2. France; 6.3.4.2.1. Market size and forecast, by Medication Class; 6.3.4.2.2. Market size and forecast, by Distribution Channel; 6.3.4.3. UK; 6.3.4.3.1. Market size and forecast, by Medication Class; 6.3.4.3.2. Market size and forecast, by Distribution Channel; 6.3.4.4. Italy; 6.3.4.4.1. Market size and forecast, by Medication Class; 6.3.4.4.2. Market size and forecast, by Distribution Channel; 6.3.4.5. Spain; 6.3.4.5.1. Market size and forecast, by Medication Class; 6.3.4.5.2. Market size and forecast, by Distribution Channel; 6.3.4.6. Rest of Europe; 6.3.4.6.1. Market size and forecast, by Medication Class; 6.3.4.6.2. Market size and forecast, by Distribution Channel; 6.4. Asia-Pacific; 6.4.1. Key market trends, growth factors and opportunities; 6.4.2. Market size and forecast, by Medication Class; 6.4.3. Market size and forecast, by Distribution Channel; 6.4.4. Market size and forecast, by country; 6.4.4.1. Japan; 6.4.4.1.1. Market size and forecast, by Medication Class; 6.4.4.1.2. Market size and forecast, by Distribution Channel; 6.4.4.2. China; 6.4.4.2.1. Market size and forecast, by Medication Class; 6.4.4.2.2. Market size and forecast, by Distribution Channel; 6.4.4.3. Australia; 6.4.4.3.1. Market size and forecast, by Medication Class; 6.4.4.3.2. Market size and forecast, by Distribution Channel; 6.4.4.4. India; 6.4.4.4.1. Market size and forecast, by Medication Class; 6.4.4.4.2. Market size and forecast, by Distribution Channel; 6.4.4.5. South Korea; 6.4.4.5.1. Market size and forecast, by Medication Class; 6.4.4.5.2. Market size and forecast, by Distribution Channel; 6.4.4.6. Rest of Asia-Pacific; 6.4.4.6.1. Market size and forecast, by Medication Class; 6.4.4.6.2. Market size and forecast, by Distribution Channel; 6.5. LAMEA; 6.5.1. Key market trends, growth factors and opportunities; 6.5.2. Market size and forecast, by Medication Class; 6.5.3. Market size and forecast, by Distribution Channel; 6.5.4. Market size and forecast, by country; 6.5.4.1. Brazil; 6.5.4.1.1. Market size and forecast, by Medication Class; 6.5.4.1.2. Market size and forecast, by Distribution Channel; 6.5.4.2. Saudi Arabia; 6.5.4.2.1. Market size and forecast, by Medication Class; 6.5.4.2.2. Market size and forecast, by Distribution Channel; 6.5.4.3. South Africa; 6.5.4.3.1. Market size and forecast, by Medication Class; 6.5.4.3.2. Market size and forecast, by Distribution Channel; 6.5.4.4. Rest of LAMEA; 6.5.4.4.1. Market size and forecast, by Medication Class; 6.5.4.4.2. Market size and forecast, by Distribution Channel
CHAPTER 7: COMPETITIVE LANDSCAPE: 7.1. Introduction; 7.2. Top winning strategies; 7.3. Product mapping of top 10 player; 7.4. Competitive dashboard; 7.5. Competitive heatmap; 7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES: 8.1. AbbVie Inc.; 8.1.1. Company overview; 8.1.2. Key executives; 8.1.3. Company snapshot; 8.1.4. Operating business segments; 8.1.5. Product portfolio; 8.1.6. Business performance; 8.2. Merck & Co., Inc.; 8.2.1. Company overview; 8.2.2. Key executives; 8.2.3. Company snapshot; 8.2.4. Operating business segments; 8.2.5. Product portfolio; 8.2.6. Business performance; 8.2.7. Key strategic moves and developments; 8.3. Boehringer Ingelheim International GmbH; 8.3.1. Company overview; 8.3.2. Key executives; 8.3.3. Company snapshot; 8.3.4. Operating business segments; 8.3.5. Product portfolio; 8.3.6. Business performance; 8.4. Gilead Sciences, Inc.; 8.4.1. Company overview; 8.4.2. Key executives; 8.4.3. Company snapshot; 8.4.4. Operating business segments; 8.4.5. Product portfolio; 8.4.6. Business performance; 8.4.7. Key strategic moves and developments; 8.5. GlaxoSmithKline plc; 8.5.1. Company overview; 8.5.2. Key executives; 8.5.3. Company snapshot; 8.5.4. Operating business segments; 8.5.5. Product portfolio; 8.5.6. Business performance; 8.5.7. Key strategic moves and developments; 8.6. Johnson & Johnson; 8.6.1. Company overview; 8.6.2. Key executives; 8.6.3. Company snapshot; 8.6.4. Operating business segments; 8.6.5. Product portfolio; 8.6.6. Business performance; 8.6.7. Key strategic moves and developments; 8.7. F. Hoffmann-La Roche Ltd.; 8.7.1. Company overview; 8.7.2. Key executives; 8.7.3. Company snapshot; 8.7.4. Operating business segments; 8.7.5. Product portfolio; 8.7.6. Business performance; 8.8. Teva Pharmaceutical Industries Ltd.; 8.8.1. Company overview; 8.8.2. Key executives; 8.8.3. Company snapshot; 8.8.4. Operating business segments; 8.8.5. Product portfolio; 8.8.6. Business performance; 8.9. Cipla Ltd.; 8.9.1. Company overview; 8.9.2. Key executives; 8.9.3. Company snapshot; 8.9.4. Operating business segments; 8.9.5. Product portfolio; 8.9.6. Business performance; 8.10. Bristol-Myers Squibb Company; 8.10.1. Company overview; 8.10.2. Key executives; 8.10.3. Company snapshot; 8.10.4. Operating business segments; 8.10.5. Product portfolio; 8.10.6. Business performance
LIST OF TABLES: TABLE 01. GLOBAL HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 02. HIV DRUGS MARKET FOR MULTI-CLASS COMBINATION DRUGS, BY REGION, 2022-2032 ($MILLION); TABLE 03. GLOBAL MULTI-CLASS COMBINATION DRUGS HIV DRUGS MARKET, BY BRAND, 2022-2032 ($MILLION); TABLE 04. HIV DRUGS MARKET FOR NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS), BY REGION, 2022-2032 ($MILLION); TABLE 05. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS) HIV DRUGS MARKET, BY BRAND, 2022-2032 ($MILLION); TABLE 06. HIV DRUGS MARKET FOR NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS), BY REGION, 2022-2032 ($MILLION); TABLE 07. GLOBAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) HIV DRUGS MARKET, BY BRAND, 2022-2032 ($MILLION); TABLE 08. HIV DRUGS MARKET FOR PROTEASE INHIBITORS (PIS), BY REGION, 2022-2032 ($MILLION); TABLE 09. GLOBAL PROTEASE INHIBITORS (PIS) HIV DRUGS MARKET, BY BRAND, 2022-2032 ($MILLION); TABLE 10. HIV DRUGS MARKET FOR ENTRY INHIBITORS, BY REGION, 2022-2032 ($MILLION); TABLE 11. GLOBAL ENTRY INHIBITORS HIV DRUGS MARKET, BY BRAND, 2022-2032 ($MILLION); TABLE 12. HIV DRUGS MARKET FOR HIV INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2022-2032 ($MILLION); TABLE 13. GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS HIV DRUGS MARKET, BY BRAND, 2022-2032 ($MILLION); TABLE 14. HIV DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION); TABLE 15. GLOBAL HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 16. HIV DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION); TABLE 17. HIV DRUGS MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION); TABLE 18. HIV DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION); TABLE 19. HIV DRUGS MARKET, BY REGION, 2022-2032 ($MILLION); TABLE 20. NORTH AMERICA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 21. NORTH AMERICA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 22. NORTH AMERICA HIV DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION); TABLE 23. U.S. HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 24. U.S. HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 25. CANADA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 26. CANADA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 27. MEXICO HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 28. MEXICO HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 29. EUROPE HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 30. EUROPE HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 31. EUROPE HIV DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION); TABLE 32. GERMANY HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 33. GERMANY HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 34. FRANCE HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 35. FRANCE HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 36. UK HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 37. UK HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 38. ITALY HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 39. ITALY HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 40. SPAIN HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 41. SPAIN HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 42. REST OF EUROPE HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 43. REST OF EUROPE HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 44. ASIA-PACIFIC HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 45. ASIA-PACIFIC HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 46. ASIA-PACIFIC HIV DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION); TABLE 47. JAPAN HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 48. JAPAN HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 49. CHINA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 50. CHINA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 51. AUSTRALIA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 52. AUSTRALIA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 53. INDIA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 54. INDIA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 55. SOUTH KOREA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 56. SOUTH KOREA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 57. REST OF ASIA-PACIFIC HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 58. REST OF ASIA-PACIFIC HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 59. LAMEA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 60. LAMEA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 61. LAMEA HIV DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION); TABLE 62. BRAZIL HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 63. BRAZIL HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 64. SAUDI ARABIA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 65. SAUDI ARABIA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 66. SOUTH AFRICA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 67. SOUTH AFRICA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 68. REST OF LAMEA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION); TABLE 69. REST OF LAMEA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION); TABLE 70. ABBVIE INC.: KEY EXECUTIVES; TABLE 71. ABBVIE INC.: COMPANY SNAPSHOT; TABLE 72. ABBVIE INC.: PRODUCT SEGMENTS; TABLE 73. ABBVIE INC.: PRODUCT PORTFOLIO; TABLE 74. MERCK & CO., INC.: KEY EXECUTIVES; TABLE 75. MERCK & CO., INC.: COMPANY SNAPSHOT; TABLE 76. MERCK & CO., INC.: PRODUCT SEGMENTS; TABLE 77. MERCK & CO., INC.: PRODUCT PORTFOLIO; TABLE 78. MERCK & CO., INC.: KEY STRATERGIES; TABLE 79. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES; TABLE 80. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT; TABLE 81. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT SEGMENTS; TABLE 82. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO; TABLE 83. GILEAD SCIENCES, INC.: KEY EXECUTIVES; TABLE 84. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT; TABLE 85. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS; TABLE 86. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO; TABLE 87. GILEAD SCIENCES, INC.: KEY STRATERGIES; TABLE 88. GLAXOSMITHKLINE PLC: KEY EXECUTIVES; TABLE 89. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT; TABLE 90. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS; TABLE 91. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO; TABLE 92. GLAXOSMITHKLINE PLC: KEY STRATERGIES; TABLE 93. JOHNSON & JOHNSON: KEY EXECUTIVES; TABLE 94. JOHNSON & JOHNSON: COMPANY SNAPSHOT; TABLE 95. JOHNSON & JOHNSON: PRODUCT SEGMENTS; TABLE 96. JOHNSON & JOHNSON: PRODUCT PORTFOLIO; TABLE 97. JOHNSON & JOHNSON: KEY STRATERGIES; TABLE 98. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES; TABLE 99. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT; TABLE 100. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS; TABLE 101. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO; TABLE 102. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES; TABLE 103. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT; TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS; TABLE 105. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO; TABLE 106. CIPLA LTD.: KEY EXECUTIVES; TABLE 107. CIPLA LTD.: COMPANY SNAPSHOT; TABLE 108. CIPLA LTD.: PRODUCT SEGMENTS; TABLE 109. CIPLA LTD.: PRODUCT PORTFOLIO; TABLE 110. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES; TABLE 111. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT; TABLE 112. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS; TABLE 113. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
LIST OF FIGURES: FIGURE 01. HIV DRUGS MARKET, 2022-2032; FIGURE 02. SEGMENTATION OF HIV DRUGS MARKET,2022-2032; FIGURE 03. TOP IMPACTING FACTORS IN HIV DRUGS MARKET (2022 TO 2032); FIGURE 04. TOP INVESTMENT POCKETS IN HIV DRUGS MARKET (2023-2032); FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS; FIGURE 06. LOW THREAT OF NEW ENTRANTS; FIGURE 07. LOW THREAT OF SUBSTITUTES; FIGURE 08. LOW INTENSITY OF RIVALRY; FIGURE 09. LOW BARGAINING POWER OF BUYERS; FIGURE 10. GLOBAL HIV DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES; FIGURE 11. HIV DRUGS MARKET, BY MEDICATION CLASS, 2022 AND 2032(%); FIGURE 12. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR MULTI-CLASS COMBINATION DRUGS, BY COUNTRY 2022 AND 2032(%); FIGURE 13. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS), BY COUNTRY 2022 AND 2032(%); FIGURE 14. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS), BY COUNTRY 2022 AND 2032(%); FIGURE 15. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR PROTEASE INHIBITORS (PIS), BY COUNTRY 2022 AND 2032(%); FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR ENTRY INHIBITORS, BY COUNTRY 2022 AND 2032(%); FIGURE 17. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR HIV INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY 2022 AND 2032(%); FIGURE 18. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%); FIGURE 19. HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%); FIGURE 20. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%); FIGURE 21. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%); FIGURE 22. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%); FIGURE 23. HIV DRUGS MARKET BY REGION, 2022 AND 2032(%); FIGURE 24. U.S. HIV DRUGS MARKET, 2022-2032 ($MILLION); FIGURE 25. CANADA HIV DRUGS MARKET, 2022-2032 ($MILLION); FIGURE 26. MEXICO HIV DRUGS MARKET, 2022-2032 ($MILLION); FIGURE 27. GERMANY HIV DRUGS MARKET, 2022-2032 ($MILLION); FIGURE 28. FRANCE HIV DRUGS MARKET, 2022-2032 ($MILLION); FIGURE 29. UK HIV DRUGS MARKET, 2022-2032 ($MILLION); FIGURE 30. ITALY HIV DRUGS MARKET, 2022-2032 ($MILLION); FIGURE 31. SPAIN HIV DRUGS MARKET, 2022-2032 ($MILLION); FIGURE 32. REST OF EUROPE HIV DRUGS MARKET, 2022-2032 ($MILLION); FIGURE 33. JAPAN HIV DRUGS MARKET, 2022-2032 ($MILLION); FIGURE 34. CHINA HIV DRUGS MARKET, 2022-2032 ($MILLION); FIGURE 35. AUSTRALIA HIV DRUGS MARKET, 2022-2032 ($MILLION); FIGURE 36. INDIA HIV DRUGS MARKET, 2022-2032 ($MILLION); FIGURE 37. SOUTH KOREA HIV DRUGS MARKET, 2022-2032 ($MILLION); FIGURE 38. REST OF ASIA-PACIFIC HIV DRUGS MARKET, 2022-2032 ($MILLION); FIGURE 39. BRAZIL HIV DRUGS MARKET, 2022-2032 ($MILLION); FIGURE 40. SAUDI ARABIA HIV DRUGS MARKET, 2022-2032 ($MILLION); FIGURE 41. SOUTH AFRICA HIV DRUGS MARKET, 2022-2032 ($MILLION); FIGURE 42. REST OF LAMEA HIV DRUGS MARKET, 2022-2032 ($MILLION); FIGURE 43. PRODUCT MAPPING OF TOP 10 PLAYERS; FIGURE 44. COMPETITIVE DASHBOARD; FIGURE 45. COMPETITIVE HEATMAP: HIV DRUGS MARKET; FIGURE 46. TOP PLAYER POSITIONING, 2022; FIGURE 47. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION); FIGURE 48. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%); FIGURE 49. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%); FIGURE 50. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION); FIGURE 51. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%); FIGURE 52. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%); FIGURE 53. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES, 2020-2022 ($MILLION); FIGURE 54. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY SEGMENT, 2022 (%); FIGURE 55. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY REGION, 2022 (%); FIGURE 56. GILEAD SCIENCES, INC.: NET REVENUE, 2020-2022 ($MILLION); FIGURE 57. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION); FIGURE 58. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%); FIGURE 59. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%); FIGURE 60. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION); FIGURE 61. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%); FIGURE 62. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%); FIGURE 63. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION); FIGURE 64. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%); FIGURE 65. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION); FIGURE 66. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%); FIGURE 67. CIPLA LTD.: SALES REVENUE, 2020-2022 ($MILLION); FIGURE 68. CIPLA LTD.: REVENUE SHARE BY SEGMENT, 2022 (%); FIGURE 69. CIPLA LTD.: REVENUE SHARE BY REGION, 2022 (%); FIGURE 70. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION); FIGURE 71. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)

PDF E-mail From Publisher:	$5,820
Data Pack/Excel E-mail From Publisher:	$3,930
Multi User License (2 - 5 Users):	$6,540
Global Site License Fulfilled by Publisher:	$9,870